PRESS
Biotricity Inc. (Biotricity) today announced its financial results for the first quarter of fiscal 2024 year ended June 30, 2023. The company reported that the Q1-FY24 revenue grew by 46.9% YOY to $3.0 million, continuing to advance toward positive cashflow.
Biotricity Inc. (Biotricity) today announced its strengthened relationships with Amazon and Google. The Company is expanding its AI technology development in remote cardiac care, leveraging its proprietary AI technology to provide a suite of predictive monitoring tools to enhance new disease profiling, improve patient management, and revolutionize the healthcare industry for disease prevention.
Biotricity Inc. (Biotricity) today announced that it received notice from The NASDAQ Stock Market LLC (NASDAQ) on July 18, 2023 informing that it has regained compliance with the minimum bid price requirement under NASDAQ Listing Rule 5550(a)(2) for continued listing on The NASDAQ Capital Market. Consequently, Biotricity is now in compliance with all applicable listing standards and its common stock will continue to be listed on The NASDAQ Capital Market.
Biotricity Inc. (Biotricity) today reported a strong start to its Fiscal Year 2024 ending March 31, 2024 and provided a preliminary estimate of its revenue for its first quarter of fiscal year 2024. For the first fiscal quarter ended June 30, 2023, the Company expects to report an approximate increase in revenue which represents growth of over 40% YOY from the corresponding prior year quarter and expects to achieve continued reduction in expenses.
Biotricity Inc. (Biotricity) today announced that it will effect a reverse stock split of its common stock. Biotricity expects its common stock to begin trading on a split-adjusted basis on the Nasdaq Capital Market as of the commencement of trading on July 3, 2023. The reverse stock split was approved by the Board of Directors of the Company and is intended to increase the per share trading price of the Company’s common stock to satisfy the $1.00 minimum bid price requirement for continued listing on the Nasdaq Capital Market.
Pursuant to the signing of a Letter of Intent (LOI) in December 2022, Seaspring W.L.L. (“Seaspring”) and Asep Medical Holdings Inc. (“Asep Inc.” or the “Company”) have signed a definitive agreement (“agreement”) for a joint venture to advance regulatory approval and commercialization of the Company’s sepsis diagnosis technology (SepsetER TM) in the Kingdom of Bahrain and the Middle East and North Africa (MENA). The terms of the definitive agreement include the formation of a 50/50 joint venture (name to be determined) whereby Seaspring will contribute the capital required (a near-term estimate of USD $5 million that is open-ended
and subject to change) by the joint venture to conduct its business operations (regulatory approval, sales and distribution) and Asep Inc. through its subsidiary Sepset Biosciences Inc., will provide the licensing rights for the use of the SepsetER technology in the Kingdom of Bahrain, Algeria, Egypt, Iran, Iraq, Israel, Jordan, Kuwait, Lebanon, Libya, Morocco, Oman, Qatar, Saudi Arabia, Syria, Tunisia, United Arab Emirates and Yemen.
